Mirvie
Mirvie is a molecular diagnostics company that uses its proprietary cell-free RNA platform and machine learning to predict pregnancy complications such as preeclampsia and preterm birth months before symptoms, selling its Encompass test direct-to-consumer and through healthcare and employer-benefit pilots.
- Company typePrivate
- Founded2018
- HeadquartersSouth San Francisco, United States
- Headcount11–50
- GTM typeB2B and B2C
- OfferingServices
What Mirvie does
Mirvie is a molecular diagnostics company that develops non-invasive blood tests designed to predict pregnancy complications months before clinical symptoms appear. Its proprietary Mirvie RNA Platform analyzes tens of thousands of cell-free RNA messages originating from the mother, baby, and placenta, combined with machine learning, to identify pregnancies at risk for preeclampsia, preterm birth, severe fetal growth restriction, and other complications. The company was founded in 2018 in South San Francisco, California, where it operates a CLIA-certified laboratory performing high-complexity clinical testing under a Breakthrough Device designation from the FDA granted in May 2022.
The company's first commercial product, the Encompass Preeclampsia Test, launched in May 2025 and is positioned as a direct-to-consumer kit taken between 18 and 22 weeks of gestation. Customers order through mirvie.com or encompassstest.com, receive a mailed kit, schedule an at-home blood draw through Getlabs mobile phlebotomists, and view results through the 1health.io platform. Encompass is bundled with a personalized preventive action plan and a responsive virtual assistant for ongoing support. Mirvie is also piloting the test with healthcare provider networks (Advantia Health) and employer benefits platforms (WIN / WINMaternity) to embed predictive screening into clinical and benefits workflows beyond DTC.
Mirvie has raised approximately $90 million in equity financing across seed and Series B rounds (notably a $60 million Series B led by Decheng Capital in May 2022), supplemented by a $15 million debt facility from Comerica Bank, a $4.6 million Bill & Melinda Gates Foundation grant for Sub-Saharan Africa research, and an additional 2025 financing reported by third-party data. Revenue is generated primarily through one-time per-test fees to consumers; the company does not publicly disclose pricing and has stated it makes no representation regarding insurance reimbursement.
Mirvie firmographics
Firmographics- Name
- Mirvie
- Legal name
- Mirvie, Inc.
- Website
- https://mirvie.com
- Company type
- Private
- Founded year
- 2018
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- Mirvie is a molecular diagnostics company that uses its proprietary cell-free RNA platform and machine learning to predict pregnancy complications such as preeclampsia and preterm birth months before symptoms, selling its Encompass test direct-to-consumer and through healthcare and employer-benefit pilots.
- Ownership category
- akta.pro rank
Mirvie industry classification
Industry- Product category
- Prenatal Diagnostic Testing
- NAICS
- Medical and Diagnostic Laboratories (6215), Medical Laboratories (621511), Research and Development in Biotechnology (except Nanobiotechnology) (541714)
- SIC
- Services-Medical Laboratories (8071), In Vitro & In Vivo Diagnostic Substances (2835)
- akta.pro primary industry
- Prenatal, Newborn & Reproductive Diagnostics (NIPT, IVF/PGT, newborn screening) (HLAAALAJ)
- akta.pro secondary industries
- Genetic & Prenatal Testing Laboratories (HLAFAMAH), Genetic, Cytogenetic & Prenatal Screening IVD (HLAHAAAI), Genetic Counseling & Prenatal Testing Telehealth (carrier screening, NIPT counseling) (HLALAHAK)
Keywords
Where Mirvie is headquartered
LocationHeadquarters
- HQ city
- South San Francisco
- HQ country
- United States
- HQ region
- North America
Offices1 record
Markets served
Mirvie business model
Business model- GTM type
- B2B and B2C
- Offering type
- Services
- Cost components
- Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure
Revenue model
- Direct-to-Consumer Diagnostic Test Sales: Mirvie sells Encompass test kits directly to pregnant consumers through its e-commerce storefronts (mirvie.com and encompassstest.com). Customers pay for the test upfront, with installment payment options available. Results are delivered through a third-party platform (1health.io).
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| One time/ perpetual license | Pay-as-you-go | Encompass Preeclampsia Test — at-home blood test with results and preventive action plan |
Go-to-market motion2 records
Distribution channels3 records
Marketing channels7 records
Mirvie product offering
Product offeringCore offering
Mirvie develops and sells the Encompass Preeclampsia Test, a non-invasive at-home blood test taken between 18-22 weeks of gestation that predicts personalized preeclampsia risk months before symptoms appear. The test is powered by the proprietary Mirvie RNA Platform, which analyzes tens of thousands of cell-free RNA messages from the baby, placenta, and mother using machine learning. The company also pursues enterprise healthcare partnerships with health systems and benefits providers to embed the test in clinical workflows.
Product overview
Mirvie offers a platform-plus-modules product architecture anchored by the Mirvie RNA Platform. The core platform combines analysis of tens of thousands of RNA messages from the baby, placenta, and mother with machine learning to predict pregnancy complications before symptoms occur. The first commercial product built on this platform is Encompass, which combines a novel blood test for personalized preeclampsia risk prediction with two supporting modules: a Preventive Action Plan and a responsive Virtual Assistant. Together, these provide pregnant women and their care teams with risk assessment, actionable guidance, and ongoing support for the healthiest pregnancy possible.
Differentiator
Problem solved
Functional benefit
Brands
- Encompass: First-of-its-kind personalized risk prediction test for preeclampsia using a simple blood test, combined with a preventive action plan and responsive virtual assistant for individualized support during pregnancy.
Products and services
- Encompass Preeclampsia Test A first-of-its-kind at-home blood test that predicts personalized preeclampsia risk months before symptoms appear, taken between 18-22 weeks of gestation. Combined with a preventive action plan and a responsive virtual assistant for individualized support throughout pregnancy. Powered by the proprietary Mirvie RNA Platform, it analyzes tens of thousands of cell-free RNA messages from the baby, placenta, and mother using machine learning. Demonstrated 75% detection rate for preeclampsia overall and 91% identification of preterm preeclampsia in women aged 35+. For pregnant women seeking proactive, personalized pregnancy care and clinicians seeking biology-driven risk stratification.
Quantifiable outcome
- Mirvie RNA platform identifies 75% of women who go on to develop preeclampsia, months before symptoms appear. Only 20% of pregnancy complications can be predicted using current generalized risk assessments.
- +4 more outcomes
Companies that use Mirvie
Customer profileNamed customers2 records
Segments3 records
Ideal customer profiles3 records
Mirvie technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Integration4 records
AI capability2 records
Feature6 records
Mirvie partnerships and signals
Strategic signalPartnerships
Six partnerships are on record, tiered core.
- WIN (WINMaternity)coreWIN (WINMaternity) partnered with Mirvie to expand its maternal health program, integrating Mirvie's Encompass test for early preeclampsia prediction and prevention. The expanded program includes 24/7 Nurse Advocacy, virtual specialists, biological data-driven screening, and engagement rewards.
- Advantia HealthcoreMirvie and Advantia Health launched a first-of-its-kind pilot program in the U.S. using the Encompass Preeclampsia Test (powered by the Mirvie RNA Platform) to assess high and low risk for preeclampsia in asymptomatic pregnant women, enabling clinicians to initiate preventive care.
- Centers for Medicare and Medicaid Services (CMS)coreMirvie's South San Francisco-based laboratory received CLIA (Clinical Laboratory Improvement Amendments) certification from CMS to perform high-complexity clinical testing, enabling the company to offer its diagnostic tests clinically.
- Getlabs, Inc.coreGetlabs provides mobile phlebotomist services for at-home blood draws for Mirvie's Encompass test. Customers schedule a blood draw through Getlabs, whose phlebotomist visits at the scheduled time and location. Use of Getlabs is subject to Getlabs Terms of Service.
- 1health.io, Inc.core1health.io delivers Mirvie test results to users through its platform. Users create a 1health account to view their Encompass results. 1health also facilitates the account registration process including a health questionnaire. Use of 1health platform is subject to 1health Terms of Use.
- Stanford University / Stephen Quake LabcoreMirvie's proprietary RNA technology was invented at Stanford University through Stephen Quake's groundbreaking work on pregnancy-related cell-free RNA. Quake co-founded Mirvie and serves as Scientific Advisory Board Chair. The technology originated from Stanford research.
Scale indicators8 records
Recent moves6 records
Expansion highlights6 records
Mirvie competitors and assessment
Company assessmentEmerging players
- Celula: Celula is an emerging diagnostics company developing cfRNA-based tests for pregnancy complications including preterm birth. It overlaps directly with Mirvie's RNA platform approach and represents a potential emerging competitor or future peer.
- Progenity: Progenity is an emerging/specialized player in reproductive and maternal health diagnostics with products in prenatal testing and maternal health. It targets a similar OB-GYN channel with a narrower portfolio, making it a relevant emerging competitor and possible tuck-in or partnership candidate.
- Akna Dx: Akna Dx is an emerging diagnostics company focused on maternal and women's health, including pregnancy complication risk. It is a smaller, more recent entrant in the same category Mirvie is building, and is a relevant emerging peer to track.
Broad incumbents
- Natera: Natera is a major reproductive health diagnostics incumbent with the Panorama NIPT, Empower carrier screen, and Vistara single-gene NIPT, plus enterprise sales infrastructure into OB-GYN offices. It is the most established competitor in the channel Mirvie is pursuing and a natural bundler for cfRNA-based predictive tests.
- Sema4 (now GeneDx): Sema4's reproductive health offering, now part of GeneDx, includes maternal screening and genetic testing. As a broader women's health and rare disease incumbent, it competes for the same hospital and health system relationships Mirvie is targeting with its enterprise pilots.
- Laboratory Corporation of America (LabCorp): LabCorp is a broad diagnostics incumbent offering the MaterniT21 NIPT and a broad prenatal screening menu. It competes with Mirvie on OB-GYN access, payer contracts, and lab throughput, and is positioned to add cfRNA-based predictive tests to its existing menu.
- Myriad Genetics: Myriad's Women's Health segment (Foresight, Prequel, SneakPeek) makes it a broad incumbent in carrier screening and NIPT. It has deep payer contracts and OB-GYN relationships that Mirvie must compete with for provider adoption of new predictive tests.
- Invitae: Invitae (now part of Labcorp) offers reproductive health genetic testing including carrier screening and NIPT. As a broad incumbent, it competes with Mirvie for the same clinical relationships and payer contracts across prenatal and women's health.
Direct peers
- Sera Prognostics: Sera Prognostics is a direct peer in pregnancy complication diagnostics, with the PreTRM test for spontaneous preterm birth risk prediction. They target the same OB-GYN and maternal-fetal medicine customer base with blood-based biomarker testing, competing head-to-head with Mirvie's preterm birth prediction offering.
- BillionToOne: BillionToOne is a high-growth prenatal diagnostics peer offering UNITY Fetal Antigen and other NIPT products that screen for pregnancy complications. It serves the same pregnant-consumer and OB-GYN segments, and is a credible DTC and enterprise competitor in advanced prenatal screening.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat5 records
Key risks6 records
Key highlights7 records
Customer concentration
Mirvie social profiles
Digital presenceMirvie compliance and trust
Trust signalCompliance1 record
Mirvie financial estimates
Financial estimateRevenue estimate
Valuation estimate
Mirvie leadership team
Management profileNumber of profiles
Profiles13 records
Mirvie funding detail
Funding detailFunding overview
Funding rounds5 records
Investors11 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Mirvie M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Mirvie
What does Mirvie do?
Mirvie develops and sells the Encompass Preeclampsia Test, a non-invasive at-home blood test taken between 18-22 weeks of gestation that predicts personalized preeclampsia risk months before symptoms appear. The test is powered by the proprietary Mirvie RNA Platform, which analyzes tens of thousands of cell-free RNA messages from the baby, placenta, and mother using machine learning. The company also pursues enterprise healthcare partnerships with health systems and benefits providers to embed the test in clinical workflows.
Is Mirvie a public or private company?
Mirvie is a private company. It is classified as venture growth investor backed and is currently operating.
When was Mirvie founded?
Mirvie was founded in 2018. It employs 11 to 50 people.
Where is Mirvie based?
Mirvie is headquartered in South San Francisco, United States, in the North America region.
How does Mirvie make money?
One revenue line is on record: direct-to-Consumer Diagnostic Test Sales.
Who are Mirvie's main competitors?
Emerging players on record are Celula, Progenity and Akna Dx. Broad incumbents are Natera, Sema4 (now GeneDx), Laboratory Corporation of America (LabCorp), Myriad Genetics and Invitae. Direct peers are Sera Prognostics and BillionToOne.
Does Mirvie have an API?
No public API is recorded for Mirvie.
What industry is Mirvie in?
Mirvie's product category is Prenatal Diagnostic Testing. Its primary akta.pro industry code is HLAAALAJ, Prenatal, Newborn & Reproductive Diagnostics (NIPT, IVF/PGT, newborn screening), with a secondary code of HLAFAMAH, Genetic & Prenatal Testing Laboratories. Its NAICS code is 6215 and its SIC code is 8071.